摘要
卵巢癌多药耐药(MDR)是导致化疗失败的一个重要原因,无创性诊断卵巢癌多药耐药一直是临床研究热点。其作用机制主要与P糖蛋白(P-gp)、MRP相关蛋白(MRP)及肺耐药蛋白(LRP)等有关。甲氧基异丁基异腈(MIBI)是P-gp、MRP共同的转运底物,细胞内99mTc-MIBI的摄取浓度与细胞上MDR表达的功能状态成反比。因此利用99mTc-MIBI功能显像对卵巢癌定性诊断、评价多药耐药及预测化疗效果,指导临床选择个体化的治疗方案可能有很高的临床应用价值。
Multidrug resistance to the chemotherapy is one of the main reasons of failure of treatment in ovarian cancer. Non - invasive diagnosis for ovarian cancer is hot topic of clinical researches. Mechanism of multidrug resistance for ovarian cancer frequently link to P - glucose protein （ P - gp ）, multidrug resistance - associated protein （MRP） ,lung resistance protein（LRP） and so on. ^99mTc -MIBI is a transmission substrate of P-gp and MRP. Uptake concentrations on ^99mTc - MIBI in the cell is revealed with the state of MDR. ^99mTc - MIBI seintigraphy has high clinical value on ovarian cancer diagnosis, multidrug resistance evaluation, chemotherapy effect prediction and offer theoretical basis for individual therapy.
出处
《现代肿瘤医学》
CAS
2009年第7期1372-1375,共4页
Journal of Modern Oncology
基金
深圳市卫生局科技计划项目基金资助(编号:JH200505270418B)
关键词
99MTC-MIBI
卵巢癌
多药耐药
^99m Tc - MIBI scintigraphy
ovarian cancer
multidrug resistance
